Stock Screener App

Frei -

Installieren

1.02

0.99% 0.01

after-market

Handel nachbörslich: 1.01 -0.01 -0.98%

Cognition Therapeutics Inc (CGTX)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Cognition Therapeutics Inc Aktie (CGTX) Neueste Nachrichten

HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings - MarketBeat

Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen - MarketBeat

CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets - MarketBeat

Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Cognition Therapeutics Inc (CGTX) Stock News Today - TradingKey

Cognition Therapeutics Stock (CGTX) Opinions on biotech upside speculation - Quiver Quantitative

Cognition Therapeutics (NASDAQ:CGTX) Releases Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Cognition Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Cognition Therapeutics, Inc. (CGTX) latest stock news and headlines - Yahoo Finance UK

Cognition Therapeutics Inc Q2 2026: Net loss $(3.9M), EPS $(0.04) — 10-Q Summary - TradingView

Cognition Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Cognition Therapeutics Q2 EPS beats estimate as R&D cuts narrow losses - scanx.trade

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Cognition Therapeutics reports Q2 2026 net loss $3.9M, cash $34.8M; plans Phase 3 in DLB psychosis - TradingView

Cognition Therapeutics Q2 net loss narrows on lower R&D costs - TradingView

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update - Yahoo Finance

Cognition Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView

CGTX News | COGNITION THERAPEUTICS INC (NASDAQ:CGTX) - ChartMill

Cognition Therapeutics (CGTX) to Post Quarterly Earnings on Thursday - MarketBeat

Cognition Therapeutics Inc (CGTX) Balance Sheet - TradingKey

Cognition Therapeutics Inc (CGTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

CGTX|Cognition Therapeutics Inc|Price:0.941|Chg%:+0.021 - TradingKey

Cognition Therapeutics Inc (CGTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Cognition Therapeutics Inc (CGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Cognition Therapeutics Inc (CGTX) Cash Flow - TradingKey

Cognition Therapeutics Inc (CGTX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Cognition Therapeutics Inc (CGTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

CGTX|Cognition Therapeutics Inc|Price:0.919|Chg%:-0.041 - TradingKey

Cognition Therapeutics Inc (CGTX) Income Statement - TradingKey

Cognition Therapeutics, Inc. Revenue Breakdown – NASDAQ:CGTX - TradingView

CGTX|Cognition Therapeutics Inc|Price:0.929|Chg%:+0.010 - TradingKey

Cognition Therapeutics (CGTX) Q2 2024 earnings summary - Quartr

CGTX Q1 2026 Earnings: Narrower-than-expected loss as clinical pipeline advancesEstimate Accuracy - po-news-eg.net

Cognition Therapeutics (CGTX) Edges Higher as Biotech Stock Tests Key ResistanceAnalyst Upgrade Stocks - dars.gov.et

Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Invest In Growth? - Sahm

Cognition Therapeutics (CGTX) Edges Lower as Stock Hovers Near Key Support LevelRVOL Breakout - dars.gov.et

RANI Stock Price and Chart — NASDAQ:RANI - TradingView

Cognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside Discussion - Quiver Quantitative

Alzheimer’s drug developer to outline Lewy body dementia Phase 3 plan - Stock Titan

Enterprise value to EBIT forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView

Can AI automation provide a survival tool amid managed care's thin margins? (CVS:NYSE) - Seeking Alpha

Enterprise value to revenue forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView

Number of shareholders of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView

Price to sales forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView

Price to earnings forward of Cognition Therapeutics, Inc. – NASDAQ:CGTX - TradingView

Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Akebia Therapeutics (AKBA) - The Globe and Mail

Cognition Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView

H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment - Investing.com South Africa

Cognition Therapeutics Slides Amid Sector Weakness; Key Support Levels in FocusTrading Ideas - dars.gov.et

We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate - Moomoo

Cognition Therapeutics, Inc.(NasdaqCM:CGTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Growth Benchmark - marketscreener.com

Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell Microcap Index - marketscreener.com

Cognition Therapeutics gets positive FDA feedback over phase 3 study of DLB psychosis – but CGTX stock just crashed 33% - MSN

Cognition Therapeutics, Inc.(NasdaqCM: CGTX) added to Russell 3000E Index - marketscreener.com

Cognition, FDA agree on late-stage trial for dementia therapy - MSN

symbol__ Stock Quote Price and Forecast - CNN

Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain - Seeking Alpha

H.C. Wainwright Remains a Buy on Coya Therapeutics, Inc. (COYA) - The Globe and Mail

Cognition Therapeutics, Inc. Actuals & Estimates (NASDAQ:CGTX) - TradingView

H.C. Wainwright Maintains Cognition Therapeutics(CGTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo

CGTX Forecast — Price Target — Prediction for 2027 - TradingView

CGTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Double-Digit Share RallyHealthcare Earnings Report - dars.gov.et

Cognition Therapeutics | 10-K: FY2025 Annual Report - Moomoo

FDA says DLB psychosis could be approvable in Cognition trial plan - Stock Titan

MRNA

$64.46

1.80%

ROIV

$36.24

0.11%

RPRX

$59.45

1.45%

INSM

$128.32

3.70%

ALNY

$224.60

1.77%

ONC

$362.51

4.33%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters